Curated News
By: NewsRamp Editorial Staff
July 10, 2025
Fifty 1 Labs Achieves Breakthrough in Long COVID Treatment with AI-Powered Trial
TLDR
- Fifty 1 Labs leverages its AI platform to lead in the $320.6 billion functional medicine market, showcasing a strategic edge in drug repurposing and personalized medicine.
- The REVIVE Adaptive Platform Trial, a Phase III study by Fifty 1 Labs, utilized AI and repurposed medicines to demonstrate treatment benefits for Long COVID in over 600 participants.
- Fifty 1 Labs' groundbreaking Long COVID trial advances personalized medicine, offering hope for better treatments and improving global health outcomes.
- Discover how Fifty 1 Labs' AI-driven trial with Stanford and Duke is revolutionizing Long COVID treatment and setting new standards in medicine.
Impact - Why it Matters
This news is pivotal as it highlights a significant advancement in the treatment of Long COVID, a condition affecting millions worldwide. The successful trial not only showcases the potential of AI in accelerating drug repurposing but also opens new avenues for personalized medicine. For investors and the healthcare industry, FITY's progress signals a promising direction in tackling post-pandemic health challenges and capitalizing on the burgeoning functional medicine market.
Summary
Fifty 1 Labs (OTC: FITY) has marked a significant milestone in the fight against Long COVID with the successful completion of the REVIVE Adaptive Platform Trial, the largest of its kind to date. This groundbreaking Phase III study, conducted in collaboration with prestigious institutions such as Stanford and Duke, utilized FITY's proprietary AI platform to demonstrate the efficacy of repurposed medicines in treating Long COVID. The trial not only sets a new benchmark in drug repurposing and personalized medicine but also aligns with FITY's ambitious strategy to dominate the $320.6 billion functional medicine market and achieve uplisting to OTCQB and Nasdaq. For more details, visit https://ibn.fm/Vq9L8.
Fifty 1 Labs, Inc., through its subsidiaries Genetic Networks LLC and 51, LLC, is at the forefront of innovation in health, wellness, and biotechnology. Genetic Networks' GeneScape platform accelerates drug discovery for personalized medicine, while 51, LLC offers a premium line of sports nutrition supplements. The company's focus on biotech and wellness synergies underscores its commitment to empowering individuals and organizations worldwide. Discover more at https://fifty1labs.com/.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Fifty 1 Labs Achieves Breakthrough in Long COVID Treatment with AI-Powered Trial
